Comparing pegaptanib and triamcinolone efficacy in the rat choroidal neovascularization model

Archives of Ophthalmology

Volumn 126, Issue 7, 2008, Pages 946-952

  Criswell, Mark H ^a   Hu, Wen Zheng ^a   Steffens, Timothy J ^a   Li, Ruihong ^b   Margaron, Philippe ^b  

^a INDIANA UNIVERSITY   (United States)

^b QLT Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGAPTANIB; TRIAMCINOLONE ACETONIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FLUORESCENCE ANGIOGRAPHY; HISTOPATHOLOGY; LASER COAGULATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBRETINAL NEOVASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; APTAMERS, NUCLEOTIDE; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; FLUORESCEIN ANGIOGRAPHY; GLUCOCORTICOIDS; INJECTIONS; LASER COAGULATION; MALE; RATS; RATS, INBRED BN; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 47549092554     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.126.7.946     Document Type: Article

References (38)

1. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25(4):581-611.
2. Bacic M, Edwards NA, Merrill MJ. Differential expression of vascular endothelial growth factor (vascular permeability factor) forms in rat tissues. Growth Factors. 1995;12(1):11-15.
3. Robinson CJ, Stringer SE. The splice variants of vascularendothelial growth factor (VEGF) and their receptors. J Cell Sci. 2001;114(pt 5):853-865.
4. Poltorak Z. Cohen T, Neufeld G. The VEGF splice variants: properties, receptors, and usage for the treatment of ischemic diseases. Herz. 2000;25(2):126-129.
5. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Hat Rev Drug Discov. 2006:5(2)123-131.
6. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina. 2002;22(2):143-152.
7. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR: for the VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related maculardegeneration. N Engl J Med. 2004;351(27):2805-2816.
8. Takahashi H, Yanagi Y, Tamaki Y, Uchida S, Muranaka K. COX-2-selective inhibitor, etodolac, suppresses choroidal neovascularization in a mice model. Biochem Biophys Res Commun. 2004;325(2):461-466.
9. Criswell MH, Temm CJ, Hu W-Z, Cornell TL, Fong S-L, Clauss MA. Temporal development of choroidal neovascularization (CNV) in the rat laser trauma model [ARVO abstract 1425], Invest Ophthalmol Vis Sci. 2005;46(suppl):1815.
10. Tzekov RT, Lin T, Oyejide A, et al. Evaluation of intravitreal application of pegaptanib sodium (Macugen®) on laser-induced CNV in cynomolgus monkeys [ARVO abstract 898], Invest Ophthalmol Vis Sci. 2006;47:2260.
11. Campochiaro PA, Hackett SF. Ocular neovascularization: a valuable model system. Oncogene. 2003;22(42):6537-6548.
12. Oshima Y, Oshima S, Nambu H, et al. Increased expression of VEGF in retinal pigmented epithelial cells is not sufficient to cause choroidal neovascularization. J Cell Physiol. 2004;201(3):393-400.
13. Campochiaro PA. Ocular versus extraocular neovascularization: mirror images or vague resemblances. Invest Ophthalmol Vis Sci. 2006:47(2):462-474.
14. Espinosa-Heidmann DG, Caicedo A, Hernandez EP, Csaky KG, Cousins SW. Bone marrow-derived progenitor cells contribute to experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44(11):4914-4919.
15. Espinosa-Heidmann DG, Reinoso MA, Pina Y, Csaky KG, Caicedo A, Cousins SW. Quantitative enumeration of vascular smooth muscle cells and endothelial cells derived from bone marrow precursors in experimental choroidal neovascularization. Exp Eye Res. 2005;80(3):369-378.
16. Sengupta N, Caballero S, Mames RN, Butler JM, Scott EW, Grant MB. The role of adult bone marrow-derived stem cells in choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44(11):4908-4913.
17. Bora PS, Sohn JH, Cruz JM, et al. Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J Immunol. 2005;174(1):491-497.
18. Sheridan CM, Rice D, Hiscott PS, Wong D, Kent DL. The presence of AC133-positive cells suggests a possible role of endothelial progenitor cells in the formation of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2006;47(4):1642-1645.
19. Keyt BA, Berleau LT, Nguyen HV, et al. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem. 1996;271(13):7788-7795.
20. Saint-Geniez M, MaldonadoAE, D'Amore PA. VEGF expression and receptor activation in the choroid during development and in the adult. Invest Ophthalmol Vis Sci. 2006;47(7):3135-3142.
21. 164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med. 2003;198(3):4B3-489.
22. Bell C, Lynam E, Landfair DJ, Janjic N, Wiles ME. Oligonucleotide NX1838 inhibits VEGF-mediated cellular responses in vitro. In Vitro Cell Dev Biol Anim. 1999;35(9):533-542.
23. 165). J Biol Chem. 1998;273(32):20556-20567.
24. 145, a secreted vascular endothelial growth isoform that binds to extracellular matrix. J Biol Chem. 1997;272(11):7151-7158.
25. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol. 2005;169(4):681-689.
26. Nozaki M, Sakurai E, Raisler BJ, et al. Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. J Clin Invest. 2006;116(2):422-429.
27. 165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 2002;62(14):4123-4131.
28. 165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004;64(21):7822-7835.
29. 165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. Mol Vis. 2006;12:626-632.
30. Zubilewicz A, Hecquet C, Jeanny J-C, Soubrane G, Courtois Y, Mascarelli F. Two distinct signalling pathways are involved in FGF2-stimulated proliferation of choriocapillary endothelial cells: a comparative study with VEGF. Oncogene. 2001;20(12):1403-1413.
31. Geisen P, McColm JR, Hartnett ME. Choroidal endothelial cells transmigrate across the retinal pigment epithelium but do not proliferate in response to soluble vascular endothelial growth factor. Exp Eye Res. 2006;82(4):608-619.
32. Rousseau B, Larrieu-Lahargue F, Bikfalvi A, Javerzat S. Involvement of fibroblast growth factors in choroidal angiogenesis and retinal vascularization. Exp Eye Res. 2003;77(2):147-156.
33. Gerritsen ME. HGF and VEGF: a dynamic duo. Circ Res. 2005;96(3):272-273.
34. Kumar R, Yoneda J, Bucana CD, Fidler IJ. Regulation of distinct steps of angiogenesis by different angiogenic molecules. Int J Oncol. 1998;12(4):749-757.
35. 165 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci. 2003;44(5):2155-2162.
36. Groop P-H, Forsblom C, Thomas MC. Mechanisms of disease: pathway-selective insulin resistance and microvascular complications of diabetes. Nat Clin Pract Endocrinol Metab. 2005;1(2):100-110.
37. Hera R, Keramidas M, Peoch M, Mouillon M, Romanet J-P, Feige J-J. Expression of VEGF and angiopoietins in subfoveal membranes from patients with age-related macular degeneration. Am J Ophthalmol. 2005;139(4):589-596.
38. Gopal L.Sharma T. Use of intravitreal injection of triamcinolone acetonide in the treatment of age-related macular degeneration. Indian J Ophthalmol. 2007;55(6):431-435.